CTRI/2020/10/028441已完成4 期
A randomized, open label, multi-center, two-treatment, two-period, two-sequence, two-way cross-over, multiple dose, steady-state Bioequivalence (BE) study of Pazopanib HCl 200mg Tablets at a dose of 800 mg (4 x 200 mg tablets) of Torrent Pharmaceuticals Ltd., India with VOTRIENT® (Pazopanib HCl 200mg) Tablets at a dose of 800 mg (4 x 200 mg tablets) of Novartis Pharmaceuticals Corporation, USA in subjects with Advanced renal cell carcinoma under fasting condition. - NA
Torrent Pharmaceuticals Ltd India0 个研究点目标入组 61 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 61
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Willing and able to provide voluntary informed consent and to follow the protocol requirements.
- •2. Subjects aged greater than 18 years having Body Mass Index at least 17.00 calculated as weight in kg per height in m2.
- •3. Subjects with confirmed diagnosis of advanced renal cell carcinoma, already receiving stable dose of Pazopanib HCl tablets of 800 mg per day since at least last 4 weeks.
- •4. Subjects able to swallow and retain oral medication
- •5. Life expectancy of at least 3 months at the time of enrolment.
- •6. Acceptable hematology status:
- •a. Hemoglobingreater than or equal to9.0 g per dL
- •b. Absolute neutrophil count greater than or equal to1500 cells per mm3
- •c. Platelet count greater than or equal to 1,00,000 cells per mm3
- •7. Acceptable liver function:
- •a. Alanine aminotransferase (ALT) less than or equal to 2 X ULN
- •b. Aspartate aminotransferase (AST) less than or equal to 2X ULN
- •c. Bilirubin less than or equal to ULN
- •d. Alkaline phosphatase less than or equal to 5 X ULN
- •8. Subjects with Creatinine clearance greater than or equal to 60 mL per minute
- •9. Cardiac ejection fraction greater than or equal to 50 Percentage by echocardiogram within 28 days of first dose of Investigational Product.
- •10. Male subjects (including those who had a vasectomy) with female partners of
- •reproductive potential must agree to use condoms from screening, during study and for at least two weeks after treatment discontinuation.
- •11. Female subjects with negative serum pregnancy test at screening and at Day 0.
- •12. Women of childbearing potential, (defined as women physiologically capable of becoming pregnant, unless they are using effective method of contraception during dosing of the investigational product) practicing acceptable methods of contraception during study and for at least two weeks after treatment discontinuation.
- •Acceptable methods of contraception are:
- •a. Oral or other (e.g. injection, patch or implant) hormonal contraception which has been used continuously for at least one month prior to the first dose of study medication
- •b. Intrauterine device IUD or intrauterine system IUD or IUS
- •c. Double barrier method of contraception Condom and occlusive cap or condom and spermicidal agent
- •d. Male sterilization at least 6 months prior to the screening, should be the sole male partner for that subject
- •e. Female sterilization surgical bilateral oophorectomy or tubal ligation at least 6 weeks prior to study participation
- •f. Total abstinence, partial abstinence is not acceptable.
- •13. No history of addiction to any recreational drug or drug dependence or alcohol addiction.
排除标准
- •1. Known hypersensitivity to Pazopanib or the components of investigational product.
- •2. History or presence of any uncontrolled systemic disease (e.g. cardiovascular disease, hypertension, diabetes mellitus etc.).
- •3. Subjects with hypokalemia, hypomagnesaemia, long QT syndrome (QTc of >450 msec in male or QTc of > 470 msec in female) or history of cardiac disease at the time of screening
- •4. Subjects found with major vascular disease or VTE in previous 6 months from the screening
- •5. Currently receiving or anticipated to receive any medications or substances that are strong inhibitors or inducers of the CYP3A4 and CYP450 inducer or inhibitor; narrow therapeutic index drugs that are metabolized by CYP3A4, CYP2D6 or CYP2C8; simvastatin, H2 receptor antagonist and PPIs. (Appendix B)
- •6. If subjects are on anti-coagulant therapy during study participation
- •7. Receiving any drugs known to prolong the QT interval within 4 weeks prior to study or during the study
- •8. Known CNS metastasis.
- •9. History or presence of Thrombotic microangiopathy (TMA) or any other dermatological toxicity.
- •10. Subjects with ECOG Performance Status of > 2.
- •11. Major surgical procedure (including periodontal) within 28 days of first dose of Investigational Product.
- •12. Surgical or other non-healing wounds.
- •13. Subjects with positive serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or Human Immunodeficiency Virus (HIV).
- •14. Subjects with current clinical or laboratory evidence of active infection.
- •15. History of other malignancies in the last 5 years
- •16. Has not recovered to Grade 0 or 1 toxicity from previous anticancer treatments or previous investigational agents. Exceptions are alopecia (any grade is acceptable), Hemoglobin greater than or equal to 9.0 g/dL, fatigue (Grade 2 is acceptable), and peripheral neuropathy (stable Grade 2 is acceptable) (As per National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], V5.0).
- •17. If subjects found positive in alcohol breath test
- •18. If subjects found positive in urine screen for drugs of abuse
- •19. Participation in any clinical study within 90 days before the first dose of Investigational Product.
- •20. Loss of greater than or equal to 350mL (1 unit) of blood within 90 days before enrollment in the study.
- •21. Any other medical condition or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the subjects to participate in the study including but not limited to cirrhosis or psychiatric illness/social situations that would limit adherence to study requirements.
- •22. Lactating women.
研究者
相似试验
已完成
1 期
Comparative study of Nilutamide 150 mg tabletCTRI/2018/01/011386Genus Lifesciences Inc40
Unknown
不适用
euprorelin Acetate Injectable Suspension 11.25 mg in male subjects with metastatic prostate cancerCTRI/2019/08/020820Daewoong Pharmaceutical Co Ltd
进行中（未招募）
不适用
Bioequivalence study in advanced renal cell carcinoma patients under fasting condition.CTRI/2022/04/041694Oncogen Pharma Malaysia Sdn Bhd
进行中（未招募）
不适用
Bioequivalence study of Olaparib Tablets 150 mg with LYNPARZA�® (Olaparib) tablets 150 mg in male or female patients with ovarian cancer or breast cancer or prostate cancer.CTRI/2021/08/035525atco Pharma Limited
进行中（未招募）
不适用
Multiple dose, steady-state relative bioavailability of Pazopanib 200 mg tablets at a dose of 800 mg (4x200 mg tablets) in subjects with advanced renal cell carcinoma under fasting condition.CTRI/2021/04/032507Oncogen Pharma Malaysia Sdn Bhd15